Dr. Ghamande on the AIM2CERV Trial in Cervical Cancer

Sharad Ghamande, MD
Published: Friday, Jan 12, 2018



Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the AIM2CERV trial for patients with cervical cancer.

According to Ghamande, the standard of care used to be radiation therapy with external and internal radiation. However, 5 years ago the addition of chemotherapy made a large difference in response rates and overall survival.

Patients with stage II advanced cervical cancer had a disease-free survival of 69% at 3 years. To date, there has not been a big difference made in these numbers, explains Ghamande.

The phase III AIM2CERV study is investigating axalimogene filolisbac (ADXS11-001) as an upfront therapy evaluating its ability to consolidate these patients who are destined to fail, and potentially prevent cervical cancer. Patients on this trial are randomized to ADXS11-001 or a placebo. This is a global trial with 150 sites in over 20 countries.
 


Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the AIM2CERV trial for patients with cervical cancer.

According to Ghamande, the standard of care used to be radiation therapy with external and internal radiation. However, 5 years ago the addition of chemotherapy made a large difference in response rates and overall survival.

Patients with stage II advanced cervical cancer had a disease-free survival of 69% at 3 years. To date, there has not been a big difference made in these numbers, explains Ghamande.

The phase III AIM2CERV study is investigating axalimogene filolisbac (ADXS11-001) as an upfront therapy evaluating its ability to consolidate these patients who are destined to fail, and potentially prevent cervical cancer. Patients on this trial are randomized to ADXS11-001 or a placebo. This is a global trial with 150 sites in over 20 countries.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Community Practice Connections™: Redefining Ovarian Cancer Treatment Paradigms by Maximizing Therapeutic Outcomes with PARP InhibitorsSep 29, 20182.0
Publication Bottom Border
Border Publication
x